|

Recombinant oncolytic herpes simplex virus type 1 (R130) Clinical Trials

2 actively recruiting trials

Also known as: Oncolytic virus

Pipeline

Early 1: 2

Top Sponsors

  • Shanghai Yunying Medical Technology2

Indications

  • Head and Neck Cancer2
  • Cancer2
  • Pharyngeal Cancer1
  • Nose Cancer1
  • Ear Cancer1

Other2 trials

A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
Early 1
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.